1. Home
  2. CGEM

CGEM

Cullinan Oncology Inc.

Logo Cullinan Oncology Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Cullinan Oncology Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted oncology therapies without bias towards specific treatment modalities. Their mission centers on setting new standards of care for cancer patients by identifying high-impact cancer targets, defined as key oncogenic drivers or immune system activators. The company's strategy involves selecting optimal therapeutic modalities for these targets. Operating as a single reporting and operating segment, the company's core business is developing early-stage cancer therapeutics, aiming to address critical needs in oncology treatment. The company's pipeline consists of CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, CLN-617.

Founded: 2016 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 733.8M IPO Year: 2021
Target Price: $28.75 AVG Volume (30 days): 492.5K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.69 EPS Growth: N/A
52 Week Low/High: $7.64 - $19.68 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 864.72%

Share on Social Networks: